The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/IIa study of GC1118 in combination with irinotecan or FOLFIRI in patients with metastatic solid tumors.
 
Keun Wook Lee
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer
Research Funding - ALX Oncology (Inst); Array BioPharma (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); Macrogenics (Inst); Merck KGaA (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
 
Sae-Won Han
No Relationships to Disclose
 
Ji-Won Kim
No Relationships to Disclose
 
Dae-Won Lee
No Relationships to Disclose
 
Yong Sang Hong
No Relationships to Disclose
 
Joong Bae Ahn
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genexine; GlaxoSmithKline; Green Cross; Hanmi; Lilly; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)